



Veterinary Medicine Research & Development
Pfizer European Service Center bvba/sprl
Hoge Wei 10, B-1930 Zaventem Belgium.

Friday 11 May 2012

Ghislaine Priem

Manager Regulatory Affairs
VMRD Regulatory Affairs
Direct Line: +32 (0)2 715 75 31
Fax Line: +32 (0)2 401 24 06
Email: Ghislaine.priem@pfizer.com

Mrs Anne-Christine Lantin
Administrative Assistant
Veterinary Regulatory and Organisational Support

European Medicines Agency
7 Westferry Circus
Canary Wharf
London - E14 4HB
United Kingdom

Subject: **Applicant's response regarding variation: EMEA/V/C/000077/II/023 for DRAXXIN 100 mg/ml Solution for Injection for Cattle and Swine**

Dear Mrs Lantin,

In response to the CVMP's request for supplementary information for the above-mentioned procedure for DRAXXIN (EMA letter dated 8 March 2012), the applicant, Pfizer Animal Health, would like to inform the EMA of its intention to withdraw the variation application: **EMEA/V/C/000077/II/023** for the addition of a *Bordetella bronchiseptica* claim for the treatment and prevention of swine respiratory disease (SRD). This decision is mainly driven by the major objections raised by the Rapporteur and Co-Rapporteur during the CVMP assessment review, in particular the failure to demonstrate efficacy with contemporary studies.

Yours sincerely

Ghislaine Priem
Manager, Regulatory Affairs